

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:818431 CAPLUS Full-text

DN 139:307638

TI Preparation of N-(3-rifamycinyl)-carbamate derivatives for their use as antituberculosis agents

IN Schueuermann, Gerrit; Kuehne, Ralph; Mekenyan, Ovanes; Nedeyalkova, Zoya Andonova; Andrew, Peter William; Shafi, Jamilia; Sharpe, Jason Anthony; Dimov, Dimcho Ivanov; Angelova, Nely Tzoneva; Grozdanov, Asenov; Penev, Pavel Nenov; Haladgova, Svetlana Tzvetkova; Mincheva, Desislava Todorova; Paraskevova, Stevka Tzvetkova; Dekin, Sashko Ivanov; Atanasova, Iskra Todorova

PA UFZ - Umweltforschungs Zentrum Leipzig-Halle G.m.b.H., Germany; University of Leicester; Balkanpharma-Razgrad Co.

SO PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084965	A1	20031016	WO 2003-EP3751	20030410
	WO 2003084965	C1	20040401		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10216719	A1	20031030	DE 2002-10216719	20020410
	AU 2003216922	A1	20031020	AU 2003-216922	20030410
	EP 1492798	A1	20050105	EP 2003-712138	20030410
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006009463	A1	20060112	US 2005-510577	20050715
PRAI	DE 2002-10216719	A	20020410		
	WO 2003-EP3751	W	20030410		

OS . CASREACT 139:307638; MARPAT 139:307638

GI



AB N-(3-rifamycinyl)-carbamate derivs., such as I [R = alkyl, alkenyl, menthyl, fluorenylmethyl, piperidyl, aryl, etc.; or salts thereof], and their corresponding hydroquinones were prepared for their use as antituberculosis agents. Thus, reaction between 3-amino rifamycin S and Me chloroformate afforded N-(methyloxycarbonyl)-3-aminorifamycin S I [R = Me (II)]. II showed 8 times higher anti-mycobacterial activity against mycobacterium tuberculosis

as compared with rifampicin. The invention also concerns a composition and a method for treating or preventing mycobacterial infections, especially tuberculosis.

IT 611205-87-9P 611205-88-0P 611205-89-1P
611205-90-4P 611205-91-5P 611205-92-6P
611205-93-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of rifamycinyl carbamate derivs. for their use as antituberculosis agents).

RN 611205-87-9 CAPLUS

CN Rifamycin, 1,4-dideoxy-3-[(ethoxycarbonyl)amino]-1,4-dihydro-1,4-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 611205-88-0 CAPLUS

CN Rifamycin, 1,4-dideoxy-1,4-dihydro-3-[(methoxycarbonyl)amino]-1,4-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 611205-89-1 CAPLUS

CN Rifamycin, 1,4-dideoxy-1,4-dihydro-3-[[[(4-nitrophenyl)methoxy]carbonyl]amino]-1,4-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 611205-90-4 CAPLUS

CN Rifamycin, 3-[[(2-bromoethoxy) carbonyl] amino]-1,4-dideoxy-1,4-dihydro-1,4-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 611205-91-5 CAPLUS

CN Rifamycin, 1,4-dideoxy-1,4-dihydro-3-[[(4-nitrophenoxy) carbonyl] amino]-1,4-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 611205-92-6 CAPLUS

CN Rifamycin, 1,4-dideoxy-1,4-dihydro-3-[[[4-(methoxycarbonyl) phenoxy] carbonyl] amino]-1,4-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 611205-93-7 CAPLUS

CN Rifamycin, 1,4-dideoxy-3-[[(4,5-dimethoxy-2-nitrophenoxy) carbonyl] amino]-
1,4-dihydro-1,4-dioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3; d his; log y
 L3 HAS NO ANSWERS
 L1 SCR 966
 L2 STR



G1 O,S,N
 G2 H,O,X
 G3 H,O
 G4

Structure attributes must be viewed using STN Express query preparation.

L3 QUE ABB=ON PLU=ON L2 AND L1

(FILE 'HOME' ENTERED AT 16:36:58 ON 11 NOV 2006)

FILE 'REGISTRY' ENTERED AT 16:37:12 ON 11 NOV 2006

L1 SCREEN 966
 L2 STRUCTURE UPLOADED
 L3 QUE L2 AND L1
 L4 0 S L3
 L5 7 S L3 FUL

FILE 'CAPLUS' ENTERED AT 16:37:49 ON 11 NOV 2006

L6 1 S L5

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.57	172.72
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

STN INTERNATIONAL LOGOFF AT 16:38:27 ON 11 NOV 2006